CDNF and Parkinson disease: After CDNF was shown to be effective in cultured cells against toxic α-synuclein oligomers,20 and in rodent and non-human primate PD models,21 the protein has entered phase I/II clinical trials in PD patients to evaluate signs of efficacy on motor functions, actigraphy measurements, and α-synuclein levels.